Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week ...
Chart does not reflect overnight price.
Find out all the key statistics for Apogee Enterprises, Inc. (APOG), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback